Onc.AI is set to showcase its innovative AI model, Serial CTRS, at the upcoming AACR Annual Meeting. This groundbreaking technology, developed in partnership with GSK, has demonstrated superior prediction abilities for overall survival in patients suffering from advanced non-small cell lung cancer (NSCLC) compared to existing methods like RECIST 1.1.
Key Points
- Serial CTRS outperformed traditional metrics such as RECIST 1.1 and tumour volume changes in predicting overall survival.
- The model can automatically evaluate routine CT images without the need for manual annotations.
- It effectively discriminates between different probabilities of 12-month overall survival in patients.
- The study validates the robustness of Serial CTRS through a blinded retrospective analysis conducted by GSK.
- Onc.AI is relying on comprehensive data from diverse healthcare systems to enhance its predictive analytics.
Content Summary
Onc.AI, a leader in AI-driven healthcare solutions, has announced that its Serial CTRS model will be presented at the 2025 AACR Annual Meeting. The model operates using routine CT imaging, aiming to define a new standard for assessing treatment response in oncology. The findings derive from collaboration with GSK during the GARNET Phase I clinical trial focused on treatable advanced NSCLC patients.
The research highlighted the model’s ability to pinpoint overall survival probabilities more accurately than current benchmark methods. Following an independent validation, results revealed Serial CTRS as a significant predictor of survival outcomes, reinforcing the idea that AI could revolutionise the clinical evaluation process in cancer treatment.
Why should I read this?
If you care about the future of cancer treatment and how AI might be changing the game, this is a must-read! Onc.AI’s Serial CTRS is not just another tech innovation; it’s a potential life-saver for patients and a critical tool for oncologists. This snapshot of cutting-edge research could directly impact how success in clinical trials is measured – so don’t miss out!